WO2008101469A3 - Pharmaceutical preparation for treating metastases - Google Patents
Pharmaceutical preparation for treating metastases Download PDFInfo
- Publication number
- WO2008101469A3 WO2008101469A3 PCT/DE2008/000264 DE2008000264W WO2008101469A3 WO 2008101469 A3 WO2008101469 A3 WO 2008101469A3 DE 2008000264 W DE2008000264 W DE 2008000264W WO 2008101469 A3 WO2008101469 A3 WO 2008101469A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- treating metastases
- substance
- lipids
- preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to novel pharmaceutical preparations and their use for the production of drugs for treating metastases, based on liposomes. These preparations are liposomal formulations. According to the invention, these formulations comprise at least one substance having an anti-tumor effect and at least one substance having an anti-coagulation effect, in addition to potentially present further agents. Particularly they are made of base lipids and optionally further components, such as helper lipids, membrane stabilizers, and charge carriers, and may have a modified surface for improving their effectiveness.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007008484.8 | 2007-02-19 | ||
DE102007008484A DE102007008484A1 (en) | 2007-02-19 | 2007-02-19 | Pharmaceutical preparation for the control of metastases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008101469A2 WO2008101469A2 (en) | 2008-08-28 |
WO2008101469A3 true WO2008101469A3 (en) | 2009-01-29 |
Family
ID=39529675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2008/000264 WO2008101469A2 (en) | 2007-02-19 | 2008-02-14 | Pharmaceutical preparation for treating metastases |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102007008484A1 (en) |
WO (1) | WO2008101469A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106541A (en) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | Compound and its medical application for strengthening PPAR γ performances and nuclear translocation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466716A (en) * | 1990-12-31 | 1995-11-14 | The Biomembrane Institute | Liposomal trimethylsphingosine |
US20050288251A1 (en) * | 2004-03-16 | 2005-12-29 | The General Hospital Corporation | Treatment and prevention of abnormal cellular proliferation |
WO2006024675A1 (en) * | 2004-09-03 | 2006-03-09 | Forschungszentrum Karlsruhe Gmbh | Use of alkylphospholipids for the treatment of solid tumours |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
EP1839648A3 (en) * | 1998-11-12 | 2007-11-21 | Transave, Inc. | An inhalation system |
DE19959689A1 (en) * | 1998-12-04 | 2000-06-08 | Max Delbrueck Centrum | Liposome composition for tumor, especially breast cancer, therapy comprises an alkyl phospholipid with antineoplastic activity and one or more antiestrogens |
US20040235792A1 (en) * | 2001-01-20 | 2004-11-25 | Deadman John J | Serine protease inhibitors compromising a hydrogen-bond acceptor |
WO2002060894A2 (en) * | 2001-01-30 | 2002-08-08 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
WO2002081467A1 (en) * | 2001-04-09 | 2002-10-17 | Ortho-Mcneil Pharmaceutical, Inc. | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
EP1416974A1 (en) * | 2001-08-16 | 2004-05-12 | Bristol-Myers Squibb Pharma Company | Gas microsphere liposome composites |
-
2007
- 2007-02-19 DE DE102007008484A patent/DE102007008484A1/en not_active Withdrawn
-
2008
- 2008-02-14 WO PCT/DE2008/000264 patent/WO2008101469A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466716A (en) * | 1990-12-31 | 1995-11-14 | The Biomembrane Institute | Liposomal trimethylsphingosine |
US20050288251A1 (en) * | 2004-03-16 | 2005-12-29 | The General Hospital Corporation | Treatment and prevention of abnormal cellular proliferation |
WO2006024675A1 (en) * | 2004-09-03 | 2006-03-09 | Forschungszentrum Karlsruhe Gmbh | Use of alkylphospholipids for the treatment of solid tumours |
Non-Patent Citations (7)
Title |
---|
D. ARNDT ET AL.: "Alkylphospholipid liposomes: preparation, properties and use in cancer research", DRUGS OF TODAY, vol. 34, 1998, pages 83 - 96, XP008059034 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002503801, retrieved from EPO Database accession no. PREV200510270367 * |
E. DIAL ET AL.: "Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.", CANCER CHEMOTER PHARMACOL, vol. 57, 2006, pages 295 - 300, XP019334299 * |
H. HAN ET AL.: "In vivo distribution and antitumor activity of heparin stabilized doxorubicin-loaded liposomes", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 313, 2006, pages 181 - 188, XP005353546 * |
R. BAZ ET AL.: "Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM)", BLOOD, vol. 104, no. 11, 2004, pages 658A - 659A * |
R. MOOG ET AL.: "Enhanced in vivo anticancer efficacy of gemcitabine after encapsulation into vesicular phospholipid gels", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, vol. 26, 1999, pages 48 - 48, XP008098661 * |
T. CHOU ET AL.: "Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method.", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 95, no. 4, 2003, pages 405 - 408, XP002503800 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106541A (en) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | Compound and its medical application for strengthening PPAR γ performances and nuclear translocation |
Also Published As
Publication number | Publication date |
---|---|
DE102007008484A1 (en) | 2008-08-21 |
WO2008101469A2 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123945T1 (en) | IMMEDIATE RELEASE ORAL FORMULATIONS FOR SUBSTITUTED QUINAZOLINONES | |
AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
CY1116075T1 (en) | NEW Liposome Compositions | |
WO2017049245A3 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
WO2005094783A3 (en) | Serum-stable amphoteric liposomes | |
WO2008042973A3 (en) | Lipid containing formulations | |
WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
WO2007064857A8 (en) | Amphoteric liposome formulation | |
NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
ATE537263T1 (en) | CATIONIC LIPIDS AND METHODS OF USE | |
WO2008063808A3 (en) | Encapsulated peptide amphiphile nanostructures | |
NZ602557A (en) | Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
WO2005063201A3 (en) | Liposomes and liposomal compositions for vaccination and drug delivery | |
EP1874793A4 (en) | Delivery of sirna by neutral lipid compositions | |
EA200801912A1 (en) | TREATMENT CANCEL | |
WO2012054500A3 (en) | Compositions for drug administration | |
WO2008030818A3 (en) | Novel liposome compositions | |
WO2008017381A8 (en) | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use | |
ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
WO2009047006A3 (en) | Amphoteric liposomes comprising neutral lipids | |
IL179012A (en) | Pharmaceutical composition comprising citerizine for the treatment of rhinitis, process for its preparation and uses thereof | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
WO2007146085A3 (en) | Creatine phosphate prodrugs, compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08715489 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08715489 Country of ref document: EP Kind code of ref document: A2 |